Healthcare / Medical DevicesNasdaqCM
$0.67
-0.02 (-2.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-11.0M · quality 58.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-249.1%
↓Gross Margin
59.8%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+122.8%
FCF CAGR
—
FCF margin
-279.4%
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.9M · net income $-12.6M · FCF $-11.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $3.9M | $3.9M | $3.3M | $2.9M | $691000.00 | $160000.00 |
| Net Income | $-12.6M | $-12.6M | $-13.7M | $-15.6M | $-18.9M | $-7.0M |
| EBITDA | $-12.0M | $-12.0M | $-13.0M | $-15.1M | $-18.3M | — |
| EPS | — | — | -11.26 | -68.72 | -188.96 | -624.80 |
| Gross Margin | 59.8% | 59.8% | 52.2% | 42.4% | -92.8% | 65.6% |
| Operating Margin | -324.3% | -324.3% | -420.1% | -537.1% | -2709.8% | -4038.1% |
| Net Margin | -318.4% | -318.4% | -417.2% | -532.1% | -2737.6% | -4405.0% |
| Balance Sheet | ||||||
| Debt/Equity | 0.03 | 0.03 | 0.07 | 2.39 | 0.15 | — |
| Current Ratio | 1.03 | 1.03 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-11.0M | $-11.0M | $-10.1M | $-12.5M | $-12.9M | $-4.4M |
| Returns | ||||||
| ROE | -249.1% | -249.1% | -229.0% | -2002.7% | -302.6% | 34.3% |
| Valuation | ||||||
| P/B | 1.45 | 1.45 | 0.44 | 3.73 | 2.06 | — |
| Growth & Yield | ||||||
| Revenue Growth | 20.4% | 20.4% | 11.9% | 323.7% | — | — |
| EPS Growth | — | — | 83.6% | 63.6% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-11.26 → n/d
Residual
-37.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.